X

RET+ NSCLC

RET+ NSCLC

Pralsetinib Demonstrates High Potency, Promise in Patients With RET+ NSCLC

Pralsetinib shows high potency, convenient oral administration, and selective RET inhibition in patients with RET-positive NSCLC, according to data from the ARROW study.

Oncology Learning Network
07/19/2021
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer

Several oncogenic drivers in non–small-cell lung cancer are considered actionable with available or promising targeted therapies.

Frontiers in Oncology
06/16/2021
Selpercatinib Superior to Prior Systemic Therapy in RET+ NSCLC

According to data from the phase 1/2 LIBRETTO-001 trial, selpercatinib demonstrated superior clinical benefit over prior systemic therapies in patients with RET+ NSCLC.

Oncology Learning Network
06/22/2021

Pralsetinib in Advanced RET Fusion–Positive NSCLC: ARROW Trial

An interim analysis of the phase I/II ARROW trial has shown that the oral RET inhibitor pralsetinib produced high response rates in previously treated and treatment-naive patients with advanced RET

The ASCO Post
06/15/2021
Pralsetinib for RET Fusion-Positive Non-Small-Cell Lung Cancer

Study investigators assess the safety, tolerability, and antitumour activity of pralsetinib, a highly potent, oral, selective RET inhibitor, in patients with RET fusion-positive NSCLC.

The Lancet Oncology
06/09/2021
Liquid Biopsy for Therapy Monitoring in Early-Stage NSCLC

Investigators review the recent research on liquid biopsy in NSCLC, not limited to ctDNA, and focus on novel methods such as micro RNAs and long non-coding.

Molecular Cancer
06/01/2021
Next-Generation Inhibitor For the Treatment of RET-altered Tumors Including RET+ NSCLC and RET-mutant MTC

During the escalation, 67 patients with RET-altered advanced solid tumors received once-daily oral doses of BOS172738 (10-150 mg).

Journal of Clinical Oncology
05/28/2021
Response to Selpercatinib versus Prior Systemic Therapy in Patients With RET Fusion+ Non-Small-Cell Lung Cancer

Selpercatinib, a first-in-class highly selective, potent, CNS-active RET kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ lung or thyroid cancers.

Journal of Clinical Oncology
05/28/2021
The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and...

Frontiers in Oncology
05/21/2021
Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation

This study evaluates the clinicopathologic significance of miR-183-3p and miR-182-5p, and the role of miR-183-3p in NSCLC progression.

Cancer Management and Research
04/28/2021
Oncogenic Driver Mutations in Non-Small Cell Lung Cancer: Past, Present and Future

This review aims to provide an update about the current landscape of driver mutation in non-small-cell lung cancer.

04/24/2021
Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions

The use of novel therapeutic drugs in lung cancer has changed the paradigm of the diagnosis and treatment of lung cancer.

Cancers
04/12/2021
The Fusion Gene Landscape in Taiwanese Patients With Non–Small-Cell Lung Cancer

Study investigators characterize the fusion gene landscape of NSCLC in a case study of Taiwanese lung cancer patients.

Cancers
03/16/2021
Integration of Comprehensive Genomic Profiling, Tumor Mutational Burden, and PD‐L1 Expression to Identify Novel Biomarkers of Immunotherapy in Non‐Small-Cell Lung Cancer

This study explores the novel biomarkers for immune checkpoint inhibitor responses in NSCLC by integrating genomic profiling, tumor mutational burden, and expression of PD‐L1.

Cancer medicine journal
03/02/2021
Therapeutic Strategies in RET Gene Rearranged Non-Small-Cell Lung Cancer

The results from the LIBRETTO-001 and ARROW clinical trials demonstrate significant clinical benefits with selpercatinib and pralsetinib respectively, in NSCLC patients with RET gene fusions...

Journal of Hematology & Oncology
03/26/2021
Combo Therapy May Target MET-Dependent Resistance in RET+ NSCLC

With the help of single patient protocols, researchers discover that combining selpercatinib with crizotinib targets MET-amplified resistance found in RET+ NSCLC treated with selpercatinib alone.

Oncology Learning Network
Selpercatinib Shows Activity in RET Fusion–Positive NSCLC and RET-Altered Thyroid Cancer

The phase I/II LIBRETTO-001 trial has shown marked activity of the RET kinase inhibitor selpercatinib in patient cohorts with RET fusion–positive NSCLC and RET-altered thyroid can

The ASCO Post
11/10/2020
Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions

Novel selective RET inhibitors like BLU-667, LOXO-292 and RXDX-105 have been recently investigated in early phase clinical trials showing promising efficacy with a manageable toxicity profile.

OncoTargets and Therapy
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer

The aim of this review is to explore recent knowledge on RET resistance in NSCLC in pre-clinic and in clinical settings and accordingly, the state-of-the-art in new drugs or combination of drugs de

Cancers
03/04/2021
ESMO Recommendations on the Standard Methods to Detect RET Fusions and Mutations in Daily Practice and Clinical Research

New selective RET inhibitors have activity and favorable toxicity profiles in RET-altered solid tumors.

Annals of Oncology
03/01/2021
Phase III Study of Selpercatinib Versus Chemotherapy ± Pembrolizumab in Untreated RET Positive Non-Small-Cell Lung Cancer

Selpercatinib demonstrates clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion positive NSCLC patients in a Phase I/II clinical tr

Future Oncology
11/05/2020
FDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLC

The FDA  approved pralsetinib (Gavreto) for the treatment of adult patients with metastatic RET fusion–positive NSCLC, as detected by an FDA-approved test. 

The ASCO Post
09/08/2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.

Characteristics and Outcomes of Patients With RET+ Non-Small Lung Cancer in Real-World Practice in the United States

This observational study was designed to compare characteristics, tumor response, PFS and OS outcomes by RET fusion status among patients with NSCLC treated with standard therapies.

BMC Cancer
01/05/2021

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834